Enhanced Genomics has appointed Dr Dietrich Stephan as Chair of the Board of Directors.
In this role, Dietrich will guide strategic initiatives including the expansion of the company’s internal pipeline, initially focused on autoimmune diseases, and the formation of partnerships to accelerate drug discovery and clinical trial stratification.
A renowned genomics expert and biotech entrepreneur, Dr Stephan has held multiple C-level and board roles, leading over two dozen private and public biotech companies through scale-up, financing and acquisition.
He has also overseen high-throughput genomics programmes, including the neuroscience genomics consortium at the US National Institutes of Health and has helped uncover the genetic drivers of hundreds of diseases.
Dietrich commented: “Enhanced Genomics’ 3D single cell-type multi-omics platform is uniquely capable of translating massive disease-associated data into actionable biology. It offers game-changing potential to identify novel, genetically validated therapeutic targets for common diseases.”
Joanna Smart, Investor Director, BGF, reflected: “Multi-omics is the next frontier of the genomics revolution — and Enhanced is leading the way. Dietrich’s track record in high-throughput genomics and biotech leadership will be pivotal as the company enters its next growth phase.”
Enhanced Genomics’ proprietary 3D multi-omics platform connects disease-associated genetic variants to causative genes in specific cell types, enabling rapid identification of high-confidence therapeutic targets.
